21 results on '"Ruettinger, Dominik"'
Search Results
2. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
3. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
4. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy
5. Akuter Thorax
6. Bispecific T Cell Engager for Cancer Therapy
7. Use of gastric residual volume to guide enteral nutrition in critically ill patients: A brief systematic review of clinical studies
8. Adjuvante therapeutische Vakzinierung beim Lungenkarzinom: erste Ergebnisse einer klinischen Pilotstudie mit autologer Tumorzell-Impfung nach Lymphopenie-Induktion und Rekonstitution mit autologen T Lymphozyten
9. Monitoring of Micro Vascular Hemoglobin Oxygenation in Liver and Skeletal Muscle Tissue of Endotoxin-Exposed Rats Using Reflection Spectrophotometry
10. Current Immunotherapeutic Strategies in Lung Cancer
11. Characterization of immune responses in gastric cancer patients: A possible impact of H. pylori to polarize a tumor-specific type 1 response?
12. Additional file 2:Â Supplementary Data. of Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
13. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody
14. Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
15. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.
16. Abstract PR04: Targeting tumor-asoociated macrophages with a novel anti-CSF1R antibody in cancer patients
17. Abstract 2940: Comprehensive biomarker program demonstrates proof of mechanism and modulation of the tumor microenvironment due to RG7155, a novel therapeutic antibody targeting tumor associated macrophages
18. Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).
19. Abstract 4719: Exploratory biomarker program in Phase I clinical development of RG7155, a novel humanized anti-CSF-1R Mab, targeting Tumor Associated Macrophages (TAMs).
20. Analysis of Tumor-Infiltrating Lymphocytes from Helicobacter pylori Positive and Negative Gastric Cancer Patients
21. In vivo assessment of hepatic alterations following gadolinium chloride-induced Kupffer cell blockade
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.